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and many of them are used for diagnosis and as prognostic or pre-
dictive tools. But till now, two challenges are remained that
requires further study: (i) the safety profile of miRNAs and (ii)
clinic delivery.
Fig. 1. PubMed query for miRNAs and cancer (September 2015).Fig. 1. Various domains that are embedded in the protein sequence of the
Diphtheria toxin. As a instance of protein sequences characterization.
Fig. 2. Binding affinity of the SDC1 to corresponding specific antigens of
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Extended Abstract
Introduction: The term ‘‘brain tumours’’ refers to a mixed group
of neoplasms originating from intracranial tissues and the meninges
with degrees of malignancy ranging from benign to aggressive.
Each type of this malignancy has its own biology, and could be lethal
due to their site in the brain, their ability to infiltrate locally, and their
propensity to transform to malignancy. Consequently, the lack of
comprehensive science of brain tumours creates problems in describ-
ing the epidemiology and therapeutic approaches. So, despite advan-
ces in conventional treatment modalities for malignant brain tumors
the prognosis for patients with high-grade astrocytic tumor remains
dismal. However, conventional treatments are accompanied with
many problems in some instances such as bleeding, hair loss, diar-
rhea, development of multidrug resistance, and immunosuppression.
Irrespective the lack of science about brain tumours and problems
that are accompanied with conventional treatments, BBB is a major
obstacle in this cancer. Therefore, there is an urgent need for the
development of novel therapies. Ideally anticancer agents for this
tumor, while could be act exclusively against tumor cells, should
be have the ability to crossing the BBB without any side effects on
the human body. Advances in genomic and proteomic research indi-
cate that treatment of brain tumor patients can be increasingly person-
alized according to the characteristics of the targeted tumor and its
environment. Nonetheless, during the last two decades, a novel class
of investigative drug candidates, Tumor-targeting protein, for the
treatment of central nervous system neoplasia has emerged. Tumor-
targeting protein which generally called immunotoxins, are composed
of a toxic enzyme coupled to a specific cell binding domain that tar-
gets cancer-associated antigens. In this context, a growing number ofthem are in different phases of the clinical and preclinical pipeline.
Bearing in mind, we investigated to designing and evaluation a new
generation of immunotoxins with capacity to targeting tumor specific
antigens of glioma as well as crossing the BBB.
Materials and methods: In this study at the first step a profile of
specific antigen of tumor brains, bacteria and their therapeutic prod-
ucts, related receptors and corresponding affecting mechanisms were
gathered. With the aim of achieving the required nucleotide and pro-
tein sequences NCBI, Uniprot and ExPASy were used. Protein
sequence analyses were done with using web application software
including InterProScan 5, CD Search and Motif Scan. 3D structure
of selected products, as well as specific antigens and their matching
ligands were retrieved or prepared via PDB, SWISS-MODEL and
or Modeller programs. Furthermore, corresponding ligands of
selected antigens were determined by using of the String. Moreover,
the protein sequences of the selected products were analyzed via Pro-
tein Blast under various matrixes. Moreover, immunogenicity assays
were performed via SVMTriPt program. Finally, the efficiency of the
3D structure of designed immunotoxins were measured with Ram-
page and visualized via Pymol.
Result and conclusion: The results of therapeutic products profil-
ing led to discovery a comprehensive profile of protein toxins with
very diverse in the resource bacteria, effective dosage, structure and
functions. However, this investigation led to finding that some of
them have previously been used in immunotoxin structure. Therefore,
critical toxins were profiled and then characterized. The result of this
analysis represented Diphtheria toxin-induced deaths domains with
ribosyltransferase functionality (Figure 1).
On the other hand, similar analysis led to disclosure effective
death domains in various toxins including glucanase domain, exo-
toxin A middle domain, and so forth with various length and activity.
Furthermore, the results of homology protein searching led to the
detection a series of similar sequences of effective domains such as
Diphtheria toxin in other species of the bacteria such as Corynebac-
terium ulcerans that propounded as novel candidate for immunotox-
ins designing. However, some of domain searching didn't have any
Fig. 3. 3D structure (A) and quality of DC-(G4S)3-DT-( G4S)3-SDC1 based on
Ramachandran assessment(B).
Fig. 1. Dendrogram of selective antioxidative enzymes.
Fig. 3. Representation complex of SODA protein with H2O2, as an instance
model.
Fig. 2. Comparison the binding affinity of the selective enzymes to H2O2 .
10 Abstracts - 1st International Nastaran Cancer Symposium-2015 / Journal of Cellular Immunotherapy 1 (2015) 1e45similarity in other species. Moreover, in-silico searching as well as
literature review led to disclosed 20 cells surface specific antigen of
brain tumors. Following, the results of corresponding ligands survey
of detected antigens led to disclosure 200 matching ligands with var-
ious in function, structure and affinity to specific antigens. However,
docking process led to disclosure SDC1 as a best ligand with capacity
to binding to four different antigens with different binding affinity
(Figure 2).
Meanwhile, assessment the post-translational modification (PTM)
of detected ligands led to disclosure that some of them are poor in
PTM. In this regard, SDC1 PTM was confined only in two sites for
phosphorylation without any glycosylation sites. On the other hand,
our survey on therapeutic products of bacteria led to exposure a
domain with ability to crossing the BBB. Finally, the assembly of
the selected domains with glycine-serine linker led to generation a
series of novel immunotoxins constructs. Subsequently, the products
assays of these constructs showed quality in structure as well as in
expression after codon optimization (Figure 3).
However, among these constructs the product of DC-(G4S)3-DT-
(G4S)3-SDC1 with the length of 462 amino acid showed the lowest
immunogenicity. Taken together, the results of this study provide a
series of cell death domain, specific ligands for targets antigen of
tumor brain, and also a new immunotoxin for target therapy.
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Extended Abstract
Introduction: Cancer is a dreadful human disease, increasing
with changing life style, nutrition, and global warming. In this con-
text, there are increasing evidences that oxidative processes andreactive oxygen species (ROS), which could be arising from indus-
trialization of the societies, caused changes in the accurate function
of the macromolecule such as DNA and proteins, which in turn
could promote various malignancies. On the other hand, several
modes of action by which carcinogens induce cancer have been
identified, including through ROS production. Antioxidants play
an important role in the later stages of cancer development via
the regression of premalignant lesions and inhibit their develop-
ment into cancer. Antioxidant enzymes, which are synthesis in
the body, and antioxidants derived of the herbs make the first and
second natural barrier, respectively, which led to neutralize, scav-
enging and or eliminate these factors. Preliminary studies have
indicated that some antioxidants, particularly b-carotene, may be
of benefit in the treatment of precancerous conditions such as
